A research team in China has reported the first non-human primate study demonstrating successful in vivo neural regeneration from brain internal glial cells for stroke repair.
They have established an ischemic stroke model in rhesus macaque monkeys aged from 9 to 21 years old to capture the typical occurrence of stroke among senior population of humans.
Using astrocyte promoter GFAP to control the expression of neural transcriptional factor NeuroD1, the study demonstrates successfully that reactive astrocytes caused by ischemic stroke in the monkey brain can be efficiently converted into neurons.
The study was led by Prof. Gong Chen at Jinan University, Guangzhou, China.
Ms. Long-Jiao Ge, the first author of the work and a PhD student in the Institute of Zoology, Chinese Academy of Sciences said: “Current treatment of ischemic stroke mainly aims at restoring blood flow and neuroprotection, typically with a narrow time window of several hours.
“However, many stroke patients cannot reach hospital within a few hours after the onset of stroke, and may suffer from a large number of neuronal death and loss of brain functions. Therefore, how to regenerate functional new neurons after stroke is the key to restore brain functions.
Explaining the original intention of this work, Prof. Chen said: “We have previously published a series of works demonstrating that overexpression of a single neural transcriptional factor NeuroD1 can directly convert glial cells into neurons in mouse brains. However, most clinical trials on stroke have failed in the past decades, suggesting that successful rodent studies may not be sufficient for clinical translation.
“Because in vivo glia-to-neuron conversion is such an innovative technology, we decided to take an important step to further validate this new technology in non-human primates”, Prof. Chen explained the original intention of this work.
“An unexpected finding is that a class of interneurons, that are sensitive to stroke injury, are significantly protected after NeuroD1 treatment, accompanied by a significant reduction of neuroinflammation. This result has important implication that in vivo astrocyte-to-neuron conversion not only regenerates new neurons but also protects the injured neurons from secondary damage, preventing further neuronal loss. Such findings of combinatorial effects of neuroregeneration plus neuroprotection may have profound impact on brain repair”, said Prof. Chen.
“What we have developed here is a unique gene therapy, using adeno-associated virus (AAV) vectors to deliver transgene NeuroD1 through direct intracranial injection into the ischemic region in primate brains. Different from classical gene therapies aiming for correction of gene mutations, our gene therapy regenerates new neurons, making it a kind of gene therapy-mediated cell therapy. We call it neuroregenerative gene therapy”, Prof. Chen commented on this innovative new technology.
“This study in non-human primates opens a new avenue using neuroregenerative gene therapy to repair damaged brains, which brings new hope to millions of patients suffering from stroke and other neurological disorders,” concluded Prof. Chen.